Cargando…
Hydroxychloroquine non-availability during COVID-19 pandemic and its relation to anxiety level and disease activity in rheumatoid arthritis and lupus patients: a cross-sectional study
BACKGROUND: During COVID-19 disease era, there is an accelerated demand for hydroxychloroquine since it was suggested by some centers as potential therapy for COVID-19 which has led to diminished supplies for patients with rheumatic disease and which carried unexpected risk for disease flare particu...
Autores principales: | Abu-Zaid, Mohammed Hassan, Aly, Hany M., Moshrif, Abdelhafeez, Abdeldaim, Doaa E., El-Ghobashy, Nehal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907908/ http://dx.doi.org/10.1186/s43166-022-00117-1 |
Ejemplares similares
-
Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients
por: da Silva, Juliana Cruz, et al.
Publicado: (2013) -
Hydroxychloroquine and Cardiovascular Events in Patients with Rheumatoid Arthritis
por: Cordova Sanchez, Andres, et al.
Publicado: (2022) -
Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: a multicenter retrospective cohort
por: Walbi, Ismail A., et al.
Publicado: (2022) -
Protective effect of hydroxychloroquine on rheumatoid arthritis‐associated atherosclerosis
por: Shi, Na, et al.
Publicado: (2019) -
Evaluating the Use of Hydroxychloroquine in Treating Patients With Rheumatoid Arthritis
por: Nazir, Armaan M, et al.
Publicado: (2021)